Brief: Glycomimetics Announces Results Of Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia
06/05/2024 11:19
May 6 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS ANNOUNCES RESULTS OF PIVOTAL PHASE 3 STUDY
OF
UPROLESELAN IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA
(AML)
* GLYCOMIMETICS INC: STUDY OF UPROLESELAN COMBINED WITH
CHEMOTHERAPY DID NOT MEET ITS PRIMARY ENDPOINT
* GLYCOMIMETICS INC - NCI PHASE 2/3 STUDY OF UPROLESELAN IN
AML
CONTINUES
* GLYCOMIMETICS: ADVERSE EVENTS CONSISTENT WITH KNOWN SIDE
EFFECT
PROFILES OF CHEMOTHERAPY USED IN STUDY
Source text for Eikon: ID:nBw4nLmdHa
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering